Do It Yourself: Advantages Of Internal Gene Therapy Manufacturing
Executive Summary
The number of gene therapies in development continues to rise, as trial sponsors widen the scope of addressable conditions, beyond ultra-rare diseases. Will manufacturing capacity – and payer budgets – be able to keep up?
You may also be interested in...
Is There A Cure For Old Age?
Investment and research into the science of aging – and therapeutics that could slow down or even reverse the aging process – are ramping up. Past clinical failures have given way to new and focused approaches that aim to lengthen “healthspan,” turning the last years of life into the best years of life.
Smart Investing: Picking Winners In Gene Therapy
Venture capitalists and industry executives discussed strategies for placing smart bets on emerging gene therapy companies during a recent virtual panel.
Gene Therapy Manufacturers Are Highly Sought Acquisition Targets
Given the transformative nature of regenerative medicines, treatments yielding greatly improved patient responses that now exist as viable products on the market, cell and gene drug developers over the past several years have been drawing deal attention. Not only through collaborative partnerships, but also as acquisition targets.